Rational Design and Synthesis of Covalent KRASG12C Inhibitors as Potential Anticancer Agents
International Journal of Drug Delivery Technology · 29.06.2026 · 16 (59s)
DOI: 10.25258/ijddt.16.59s.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 29.06.2026. Verfasst von Lala S. Rathod und 2 weiteren Autor:innen.
Abstract (Originalsprache)
The presence of KRAS mutations is one of the most common reasons of oncogenic transformation of human cells. In particular, the KRASG12C mutation is observed quite often in non-small cell lung cancer, colorectal cancer, and pancreatic cancer. The substitution of glycine for cysteine at position 12 results in the creation of a specific nucleophile residue which provides possibilities for selective and irreversible targeting, thus, allowing for precision oncology. In this work, a novel series of covalent KRASG12C inhibitors was designed on the basis of a rational structure-based approach aimed at the inhibition of inactive G-DP bound mutant KRASG12C protein in the allosteric switch-II pocket. The synthesized molecules were characterized by standard methods and then tested for anticancer activity both in silico and in vitro. In particular, molecular docking experiments showed proper binding to key residues of the switch-II pocket and covalent attachment to the Cys12 residue of mutant KRASG12C protein. Moreover, cytotoxic activity against various KRAS-mutant cancer cell lines was determined in order to estimate the ability of the synthesized molecules to disrupt KRAS-mediated downstream signaling pathways. This study demonstrates the value of using rational design approaches to generate selective KRASG12C inhibitors through covalent binding, and also sheds some light on SARs that could assist future optimization of these agents.
Zitieren
APA
Rathod, L. S., Mokale, S. N., & Mokale, V. (2026). Rational Design and Synthesis of Covalent KRASG12C Inhibitors as Potential Anticancer Agents. International Journal of Drug Delivery Technology, 16(59s). https://doi.org/10.25258/ijddt.16.59s.2
Vancouver
Rathod LS, Mokale SN, Mokale V. Rational Design and Synthesis of Covalent KRASG12C Inhibitors as Potential Anticancer Agents. International Journal of Drug Delivery Technology. 2026;16(59s). doi:10.25258/ijddt.16.59s.2
BibTeX
@article{Rathod2026,
author = {Rathod, Lala S. and Mokale, Santosh N. and Mokale, Vinod},
title = {Rational Design and Synthesis of Covalent KRASG12C Inhibitors as Potential Anticancer Agents},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {59s},
doi = {10.25258/ijddt.16.59s.2}
}
EUVIMED